Shanghai Fosun Pharmaceutical (600196.SH): The drug registration application for Fosun acyclovir capsule has been accepted.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. has recently had its drug registration application for Fosinexil Citrate Capsules (project code: FCN-437c, registration category: Category 1) accepted by the National Medical Products Administration. The indication for this application is for use in locally advanced or metastatic breast cancer that is hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, to be used in combination with aromatase inhibitors as initial endocrine therapy for premenopausal, postmenopausal, and peri-menopausal women with breast cancer.